Popular on Rezul
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 181
- JiT Home Buyers Expands Local Presence to 18 Real Estate Markets Across the United States - 156
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention - 143
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety - 135
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma - 133
- Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI - 112
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards - 104
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
- PulteGroup expands Northeast Florida presence with Oakmere coming soon to Mandarin
- DuoKey launches the World's First Agentic Crypto Agility Platform
Similar on Rezul
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Mandeville Pests May Pose Serious Health Risks for Your Family
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
Veterans Day: CCHR Calls for Safeguards Against Drugging & Electroshocking Vets
Rezul News/10685323
The mental health watchdog says the VA and DoD waste billions of dollars on treatments that contribute to high suicide rates, sudden deaths and brain damage in veterans, and are investing in psychedelics that further harm
LOS ANGELES - Rezul -- On Veteran's Day, November 11, the Citizens Commission on Human Rights (CCHR) International honors veterans and calls for an end to subjecting them to cocktails of psychotropic drugs, psychedelics and electroshock treatment to treat their trauma and mental health issues. CCHR re-launched its documentary Hidden Enemy: Inside Psychiatry's Covert Agenda, featuring interviews with over 80 soldiers and experts who shatter the idea that these "treatments" have helped. Produced as a public service for active-duty soldiers, veterans and their families, the documentary provides information that the psychiatric-pharmaceutical industry does not divulge.
The documentary reveals how treatments provided to veterans very likely contribute to, and even induce, suicidal thoughts and actions. According to the U.S. Army Institute of Public Health, 46% of those who completed suicides, 90% of those who attempted suicides, and 87% of those with suicidal ideation received a Central Nervous System (CNS)-acting prescription in the year preceding the event.[1]
U.S. veterans account for about 13.9% of suicides among adults in the U.S. In 2019, 1.6% of veterans ages 18-25 reported making a suicide attempt during the previous 12 months.[2]
Dr. Bart Billings, a retired U.S. Army psychologist who has treated thousands of veterans suffering from trauma maintains that there is "a direct correlation" between the increased use of psychiatric drugs to treat this and the high rate of military suicides. He believes "probably 90 percent of psychiatrists, if not more, prescribe psychiatric medications. That's basically all they do. They don't do therapy anymore."
CCHR files Freedom of Information Act requests to the Department of Defense (DoD) and Veteran Affairs (VA) and found that between 2018 and 2023, the administration spent over $2.5 billion on psychotropic drugs. In 2023, 2.3 million vets were taking these drugs, of which: 66% (1.53 million) were on antidepressants; 43% (nearly 1 million) took mood stabilizers; 30% (697,174) were on anti-anxiety/sedatives and 13% (302,534) took antipsychotics.
More on Rezul News
The highest costs were for antipsychotics (49%) at $1,257,895,937; mood stabilizers costing $638,449,228 (25%) and antidepressants costing $416,322,108 (16%).[3]
CCHR says service members and veterans should never be put at risk of suicide from antidepressants, which carry a Food and Drug Administration (FDA) "black-box" warning of "suicidality" for those younger than 25. A CCHR submission to the VA pointed out that 41% of deployed American soldiers were 18-24, which means those prescribed antidepressants were put at greater risk of suicide.[4]
Internationally respected researcher Peter C. Gøtzsche, M.D. recently published a critique of the practices of suicide experts who claim antidepressants are effective for suicide prevention, arguing that they selectively present research and overlook evidence that contradicts their claims. Rather, he says, the drugs can actually double the likelihood of suicide rates. According to one study he cited, antidepressants increase the risk of repeated suicide attempts by 50%.[5]
When antidepressants fail, more invasive treatments, such as electroconvulsive Therapy (ECT) or electroshock is recommended. ECT involves the passage of up to 460 volts of electricity through the brain to induce a grand mal seizure, which can lead to brain damage.
Through a FOIA request to the VA, CCHR found that from 2018 to 2023, 2,527 veterans received ECT at a cost of $22.8 million—an amount reflecting only the VA's expenditures. Between 2010 and 2019 Tricare, the uniformed services health care program for active-duty service members and their families, paid $17.6 million on ECT delivery. The number of military and their family members who received ECT increased by 13% (from 648 people in 2010 to 732 people in 2019). The largest increase was in those aged 18–24 — a 226% increase.
Last year, a study published in Acta Psychiatrica Scandinavica found that after receiving electroshock treatment, patients were 44 times more likely to die by suicide than people in the general population.[6]
A new retrospective study published in BMC Psychiatry also points to ECT's failure. It found that patients who received ECT were more likely to be rehospitalized and had longer hospital stays compared to those who did not receive it. The rehospitalization rate for ECT recipients was 37.52% versus 20.71% for non-ECT patients. ECT patients also had significantly longer stays (average 14.53 days vs. 6.54 days for non-ECT). Females received ECT more often, while males had higher rehospitalization rates.[7]
More on Rezul News
With such high failure rates, the Department of Veteran Affairs is now prospecting psychedelic substances such as MDMA (Ecstasy), and psilocybin (magic mushrooms) to treat PTSD and depression. Yet a 2023 study published in Scientific Reports reported, "Unpleasant acute psychological experiences under psychedelics are not rare—even in research environments. For example, one notable study reported an approximately 40% prevalence of moderate to severe anxiety, panic or distress with high dose psilocybin in healthy volunteers."[8]
Dr. Gøtzsche advises that we could reduce our current usage of psychotropic drugs by 98% and at the same time improve patients' mental and physical health and survival.
CCHR, established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, urges an immediate shift away from harmful psychiatric treatments that put veterans at risk of worsening mental health and even suicide. It also calls for greater transparency and accountability within the VA and DoD. "Veterans deserve care that prioritizes their well-being, not quick-fix, pharmaceutical-based solutions that aren't effective and often make their situations worse." Veterans are invited to visit CCHR's Museum: Psychiatry: An Industry of Death, 6616 Sunset Blvd., Los Angeles, California. Open Monday-Saturday, 10 a.m. - 5 p.m.
[1]
www.hsrd.research.va.gov/research/citations/PubBriefs/articles.cfm?RecordID=783
[2] www.cdc.gov/suicide/disparities/?CDC_AAref_Val=https://www.cdc.gov/suicide/facts/disparities-in-suicide.html
[3] www.cchrint.org/2021/09/13/cchrs-foia-request-to-veteran-health-administration-reveals-4-2-million-vets-prescribed-dangerous-drugs-costing-2-4-billion/
[4] www.cchrint.org/2020/11/11/cchr-urges-new-military-va-law-to-expand-study-into-all-psychotropic-drug-deaths/; www.cardin.senate.gov/newsroom/press/release/cardin-calls-for-scientific-study-to-determine-extent-of-link-between-antidepressant-use-by-combat-troops-and-military-suicide-rate
[5] www.madinamerica.com/2024/10/so-called-suicide-experts-recommend-antidepressants-which-increase-suicides/
[6] www.madinamerica.com/2023/02/ect-does-not-seem-to-prevent-suicide/
[7] bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06211-2
[8] www.cchrint.org/2024/01/12/cchr-calls-for-ceasing-psychedelic-drug-trials-on-military-and-veterans/; www.nature.com/articles/s41598-023-41145-x
The documentary reveals how treatments provided to veterans very likely contribute to, and even induce, suicidal thoughts and actions. According to the U.S. Army Institute of Public Health, 46% of those who completed suicides, 90% of those who attempted suicides, and 87% of those with suicidal ideation received a Central Nervous System (CNS)-acting prescription in the year preceding the event.[1]
U.S. veterans account for about 13.9% of suicides among adults in the U.S. In 2019, 1.6% of veterans ages 18-25 reported making a suicide attempt during the previous 12 months.[2]
Dr. Bart Billings, a retired U.S. Army psychologist who has treated thousands of veterans suffering from trauma maintains that there is "a direct correlation" between the increased use of psychiatric drugs to treat this and the high rate of military suicides. He believes "probably 90 percent of psychiatrists, if not more, prescribe psychiatric medications. That's basically all they do. They don't do therapy anymore."
CCHR files Freedom of Information Act requests to the Department of Defense (DoD) and Veteran Affairs (VA) and found that between 2018 and 2023, the administration spent over $2.5 billion on psychotropic drugs. In 2023, 2.3 million vets were taking these drugs, of which: 66% (1.53 million) were on antidepressants; 43% (nearly 1 million) took mood stabilizers; 30% (697,174) were on anti-anxiety/sedatives and 13% (302,534) took antipsychotics.
More on Rezul News
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Phoenix REALTOR® Jennifer Alvarez Expands Resources for Attorneys and Clients Navigating Complex Real Estate Matters
- Fairhope Home Prices Hold Steady Through August 2026 as Sales Pace Slows
- Stockdale Capital Partners Launches Real Estate Credit Platform
The highest costs were for antipsychotics (49%) at $1,257,895,937; mood stabilizers costing $638,449,228 (25%) and antidepressants costing $416,322,108 (16%).[3]
CCHR says service members and veterans should never be put at risk of suicide from antidepressants, which carry a Food and Drug Administration (FDA) "black-box" warning of "suicidality" for those younger than 25. A CCHR submission to the VA pointed out that 41% of deployed American soldiers were 18-24, which means those prescribed antidepressants were put at greater risk of suicide.[4]
Internationally respected researcher Peter C. Gøtzsche, M.D. recently published a critique of the practices of suicide experts who claim antidepressants are effective for suicide prevention, arguing that they selectively present research and overlook evidence that contradicts their claims. Rather, he says, the drugs can actually double the likelihood of suicide rates. According to one study he cited, antidepressants increase the risk of repeated suicide attempts by 50%.[5]
When antidepressants fail, more invasive treatments, such as electroconvulsive Therapy (ECT) or electroshock is recommended. ECT involves the passage of up to 460 volts of electricity through the brain to induce a grand mal seizure, which can lead to brain damage.
Through a FOIA request to the VA, CCHR found that from 2018 to 2023, 2,527 veterans received ECT at a cost of $22.8 million—an amount reflecting only the VA's expenditures. Between 2010 and 2019 Tricare, the uniformed services health care program for active-duty service members and their families, paid $17.6 million on ECT delivery. The number of military and their family members who received ECT increased by 13% (from 648 people in 2010 to 732 people in 2019). The largest increase was in those aged 18–24 — a 226% increase.
Last year, a study published in Acta Psychiatrica Scandinavica found that after receiving electroshock treatment, patients were 44 times more likely to die by suicide than people in the general population.[6]
A new retrospective study published in BMC Psychiatry also points to ECT's failure. It found that patients who received ECT were more likely to be rehospitalized and had longer hospital stays compared to those who did not receive it. The rehospitalization rate for ECT recipients was 37.52% versus 20.71% for non-ECT patients. ECT patients also had significantly longer stays (average 14.53 days vs. 6.54 days for non-ECT). Females received ECT more often, while males had higher rehospitalization rates.[7]
More on Rezul News
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
With such high failure rates, the Department of Veteran Affairs is now prospecting psychedelic substances such as MDMA (Ecstasy), and psilocybin (magic mushrooms) to treat PTSD and depression. Yet a 2023 study published in Scientific Reports reported, "Unpleasant acute psychological experiences under psychedelics are not rare—even in research environments. For example, one notable study reported an approximately 40% prevalence of moderate to severe anxiety, panic or distress with high dose psilocybin in healthy volunteers."[8]
Dr. Gøtzsche advises that we could reduce our current usage of psychotropic drugs by 98% and at the same time improve patients' mental and physical health and survival.
CCHR, established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, urges an immediate shift away from harmful psychiatric treatments that put veterans at risk of worsening mental health and even suicide. It also calls for greater transparency and accountability within the VA and DoD. "Veterans deserve care that prioritizes their well-being, not quick-fix, pharmaceutical-based solutions that aren't effective and often make their situations worse." Veterans are invited to visit CCHR's Museum: Psychiatry: An Industry of Death, 6616 Sunset Blvd., Los Angeles, California. Open Monday-Saturday, 10 a.m. - 5 p.m.
[1]
www.hsrd.research.va.gov/research/citations/PubBriefs/articles.cfm?RecordID=783
[2] www.cdc.gov/suicide/disparities/?CDC_AAref_Val=https://www.cdc.gov/suicide/facts/disparities-in-suicide.html
[3] www.cchrint.org/2021/09/13/cchrs-foia-request-to-veteran-health-administration-reveals-4-2-million-vets-prescribed-dangerous-drugs-costing-2-4-billion/
[4] www.cchrint.org/2020/11/11/cchr-urges-new-military-va-law-to-expand-study-into-all-psychotropic-drug-deaths/; www.cardin.senate.gov/newsroom/press/release/cardin-calls-for-scientific-study-to-determine-extent-of-link-between-antidepressant-use-by-combat-troops-and-military-suicide-rate
[5] www.madinamerica.com/2024/10/so-called-suicide-experts-recommend-antidepressants-which-increase-suicides/
[6] www.madinamerica.com/2023/02/ect-does-not-seem-to-prevent-suicide/
[7] bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06211-2
[8] www.cchrint.org/2024/01/12/cchr-calls-for-ceasing-psychedelic-drug-trials-on-military-and-veterans/; www.nature.com/articles/s41598-023-41145-x
Source: Citizens Commission on Human Rights
0 Comments
Latest on Rezul News
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Downtown Sarasota Luxury Condo Sales Rise 39.8% Through August 2026 as Marketing Time Lengthens
- BIC Homes Offers Affordable Luxury New Homes in Northeast El Paso, TX
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Indian Shores STR Condo Sales Rise 50% Year to Date as Median Price Falls 7% in 2026
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Land For Sale Lake Conroe TX – Lots & Acreage
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- ClearLead Digital Launches New Website for Smart Move Property Management
- David Weekley Homes Debuts Three New Floor Plans in Forsyth County
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- Rural California Energy Consultancy Unlocks Remote Sites for Vacation Rentals and ADUs
- Apple Valley Home Sales Rise 22.0% as Active Listings Fall 20.2%
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
